Abstract 314P
Background
ES-SCLC is a highly aggressive type of lung cancer with a high risk of early progression and limited survival. Standard-of-care for first-line treatment is platinum-etoposide chemotherapy plus anti-PDL1 immune checkpoint inhibitors.
Methods
CLINATEZO is a nationwide, non-interventional, retrospective study of consecutive patients (pts) with ES-SCLC who received atezolizumab plus platinum-based chemotherapy as part of the French EAP that ran from May 2019 to March 2020. In this analysis, predictors of long-term response (defined by a real-world progression-free survival (rwPFS)>12 months) and long-term survival (defined by an overall survival (OS)>24 months) were assessed.
Results
518 patients were enrolled from 65 centers. After a median follow-up of 53.8 months, median, 12-months and 48 months rwPFS rate were 5.2 months, 14.6% and 6.8%. Median, 24-months and 48 months OS rate were 11.3 months, 21.1% and 11.4%. Long-term response was observed in 12.5% pts. Median rwPFS was 9.7 months in pts with rwPFS≤12 months and 53.7 months in pts with rwPFS>12 months. At multivariate regression analysis, the only predictor factor in favor for rwPFS>12 months was former smokers (vs. current smokers, p=0.002). Long-term survival was observed in 20.5% pts. Median OS was 8.8 months in pts with OS≤24 months and 52.9 months in pts with OS>24 months. At multivariate regression analysis, predictor factor of long-term survival was the low number of pack-years (p=0.02).
Conclusions
CLINATEZO shows the reproducibility of the key survival outcomes of landmark trials, in a real-life setting, for pts with ES-SCLC. Only low smoking history was associated with long-term response and survival in our cohort.
Clinical trial identification
NCT04920981.
Legal entity responsible for the study
IFCT French Cooperative Thoracic Intergroup.
Funding
Hoffmann-LaRoche.
Disclosure
L. Falchero: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Sanofi. K. Amrane: Financial Interests, Personal, Other, Local Meeting: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Other, congress invitation: Pfizer. B. Godbert: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Janssen-Cilag, Pfizer; Financial Interests, Personal, Invited Speaker: BMS, MSD, AstraZeneca. J. Madelaine: Non-Financial Interests, Personal, Invited Speaker: Pfizer SAS, AstraZeneca, Pierre Fabre, MSD. P. Fournel: Financial Interests, Personal, Advisory Board: BMS, MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca, Amgen, Sanofi; Financial Interests, Personal, Other, Congress invitation: Takeda. C. Mascaux: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, MSD, Amgen, Janssens; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Kephren, Janssens, Takeda, Sanofi, Novartis. J. Raimbourg: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Pierre Fabre, Amgen, Sanofi; Financial Interests, Institutional, Advisory Board: Takeda, BMS, Merck. V. Westeel: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Pfizer; Financial Interests, Personal, Other, scientific committee and invited speaker: MSD; Financial Interests, Personal, Invited Speaker, and scientific committee: Roche, Amgen; Financial Interests, Personal, Invited Speaker, and board: Sanofi; Financial Interests, Institutional, Other, local PI: Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: MSD, Roche, Daiichi Sankyo, Merck, Amgen, Seagen, Ose Immunotherapeutics; Other, Personal, Other, support for meeting attendance: AstraZeneca, Bristol Myers Squibb, Janssen; Other, Personal, Other, Support for meeting attendance: MSD, Amgen. N. Girard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Regeneron, AbbVie, Amgen, Lilly, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen, Pierre Fabre, BeiGene; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Pfizer, Amgen, MSD, Sanofi, Gilead, Janssen; Financial Interests, Personal, Officer: Edimark; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Personal, Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest.